![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TAP2 |
Gene summary for TAP2 |
![]() |
Gene information | Species | Human | Gene symbol | TAP2 | Gene ID | 6891 |
Gene name | transporter 2, ATP binding cassette subfamily B member | |
Gene Alias | ABC18 | |
Cytomap | 6p21.32 | |
Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | Q03519 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6891 | TAP2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.80e-07 | 2.32e-01 | -0.1808 |
6891 | TAP2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.73e-09 | 2.54e-01 | -0.0811 |
6891 | TAP2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.02e-14 | 2.78e-01 | -0.1954 |
6891 | TAP2 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.61e-03 | 2.55e-01 | -0.2602 |
6891 | TAP2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.29e-05 | 3.96e-01 | -0.2196 |
6891 | TAP2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.09e-06 | 2.67e-01 | -0.1207 |
6891 | TAP2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.47e-06 | 2.84e-01 | -0.1526 |
6891 | TAP2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.80e-25 | 4.61e-01 | -0.1464 |
6891 | TAP2 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.05e-06 | 1.52e-01 | -0.1001 |
6891 | TAP2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.44e-15 | 3.88e-01 | -0.059 |
6891 | TAP2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.52e-06 | 3.82e-01 | -0.2061 |
6891 | TAP2 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.17e-02 | 1.52e-01 | -0.0842 |
6891 | TAP2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.67e-10 | 2.88e-01 | 0.096 |
6891 | TAP2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 6.81e-04 | 2.58e-01 | 0.0131 |
6891 | TAP2 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.85e-04 | 2.69e-01 | 0.0171 |
6891 | TAP2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.92e-04 | 1.44e-01 | 0.0674 |
6891 | TAP2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.30e-41 | 7.92e-01 | 0.294 |
6891 | TAP2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.40e-05 | 7.22e-01 | 0.3487 |
6891 | TAP2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.91e-05 | 2.35e-01 | 0.281 |
6891 | TAP2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.93e-21 | 4.33e-01 | 0.3859 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0015833 | Colorectum | AD | peptide transport | 77/3918 | 264/18723 | 8.90e-04 | 8.60e-03 | 77 |
GO:0002483 | Colorectum | AD | antigen processing and presentation of endogenous peptide antigen | 10/3918 | 19/18723 | 2.25e-03 | 1.77e-02 | 10 |
GO:0042886 | Colorectum | AD | amide transport | 83/3918 | 301/18723 | 3.37e-03 | 2.46e-02 | 83 |
GO:0019883 | Colorectum | AD | antigen processing and presentation of endogenous antigen | 12/3918 | 26/18723 | 3.47e-03 | 2.51e-02 | 12 |
GO:00198831 | Colorectum | SER | antigen processing and presentation of endogenous antigen | 11/2897 | 26/18723 | 9.60e-04 | 1.15e-02 | 11 |
GO:00024831 | Colorectum | SER | antigen processing and presentation of endogenous peptide antigen | 9/2897 | 19/18723 | 1.05e-03 | 1.23e-02 | 9 |
GO:0048002 | Colorectum | SER | antigen processing and presentation of peptide antigen | 19/2897 | 62/18723 | 1.96e-03 | 1.97e-02 | 19 |
GO:0019885 | Colorectum | SER | antigen processing and presentation of endogenous peptide antigen via MHC class I | 8/2897 | 17/18723 | 2.12e-03 | 2.06e-02 | 8 |
GO:0019882 | Colorectum | SER | antigen processing and presentation | 28/2897 | 106/18723 | 2.52e-03 | 2.34e-02 | 28 |
GO:00158331 | Colorectum | SER | peptide transport | 58/2897 | 264/18723 | 3.08e-03 | 2.70e-02 | 58 |
GO:00158332 | Colorectum | MSS | peptide transport | 71/3467 | 264/18723 | 4.79e-04 | 5.60e-03 | 71 |
GO:00024832 | Colorectum | MSS | antigen processing and presentation of endogenous peptide antigen | 10/3467 | 19/18723 | 8.39e-04 | 8.68e-03 | 10 |
GO:00198832 | Colorectum | MSS | antigen processing and presentation of endogenous antigen | 12/3467 | 26/18723 | 1.16e-03 | 1.12e-02 | 12 |
GO:00428861 | Colorectum | MSS | amide transport | 76/3467 | 301/18723 | 2.14e-03 | 1.80e-02 | 76 |
GO:00198851 | Colorectum | MSS | antigen processing and presentation of endogenous peptide antigen via MHC class I | 8/3467 | 17/18723 | 6.76e-03 | 4.38e-02 | 8 |
GO:00024833 | Colorectum | MSI-H | antigen processing and presentation of endogenous peptide antigen | 10/1319 | 19/18723 | 1.49e-07 | 1.32e-05 | 10 |
GO:00198833 | Colorectum | MSI-H | antigen processing and presentation of endogenous antigen | 11/1319 | 26/18723 | 5.86e-07 | 4.28e-05 | 11 |
GO:00198852 | Colorectum | MSI-H | antigen processing and presentation of endogenous peptide antigen via MHC class I | 8/1319 | 17/18723 | 8.12e-06 | 3.99e-04 | 8 |
GO:00480021 | Colorectum | MSI-H | antigen processing and presentation of peptide antigen | 13/1319 | 62/18723 | 3.19e-04 | 7.63e-03 | 13 |
GO:0002474 | Colorectum | MSI-H | antigen processing and presentation of peptide antigen via MHC class I | 8/1319 | 28/18723 | 5.16e-04 | 1.07e-02 | 8 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516332 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa020103 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
hsa0516928 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa0517027 | Oral cavity | OSCC | Human immunodeficiency virus 1 infection | 133/3704 | 212/8465 | 1.42e-08 | 1.40e-07 | 7.12e-08 | 133 |
hsa0516328 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
hsa0414528 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
hsa0461229 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa05169113 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa05170111 | Oral cavity | OSCC | Human immunodeficiency virus 1 infection | 133/3704 | 212/8465 | 1.42e-08 | 1.40e-07 | 7.12e-08 | 133 |
hsa05163112 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
hsa04145113 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
hsa04612113 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa0516929 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa0414529 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
hsa0517028 | Oral cavity | LP | Human immunodeficiency virus 1 infection | 92/2418 | 212/8465 | 2.18e-06 | 2.20e-05 | 1.42e-05 | 92 |
hsa04612210 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0516329 | Oral cavity | LP | Human cytomegalovirus infection | 85/2418 | 225/8465 | 1.55e-03 | 6.89e-03 | 4.45e-03 | 85 |
hsa0516936 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa0414536 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
hsa0517037 | Oral cavity | LP | Human immunodeficiency virus 1 infection | 92/2418 | 212/8465 | 2.18e-06 | 2.20e-05 | 1.42e-05 | 92 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAP2 | insertion | In_Frame_Ins | novel | c.1468_1469insTCATAAGAGATGGTG | p.Thr490delinsIleIleArgAspGlyAla | p.T490delinsIIRDGA | Q03519 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
TAP2 | SNV | Missense_Mutation | c.94N>T | p.Pro32Ser | p.P32S | Q03519 | protein_coding | deleterious(0.02) | benign(0.103) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
TAP2 | SNV | Missense_Mutation | c.1079N>C | p.Glu360Ala | p.E360A | Q03519 | protein_coding | tolerated(0.21) | possibly_damaging(0.634) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TAP2 | SNV | Missense_Mutation | c.1414N>A | p.Asp472Asn | p.D472N | Q03519 | protein_coding | tolerated(0.87) | benign(0.001) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TAP2 | SNV | Missense_Mutation | rs769546391 | c.872N>A | p.Arg291Gln | p.R291Q | Q03519 | protein_coding | tolerated(0.39) | possibly_damaging(0.672) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TAP2 | SNV | Missense_Mutation | c.1600N>G | p.Ile534Val | p.I534V | Q03519 | protein_coding | tolerated(0.32) | benign(0.017) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TAP2 | SNV | Missense_Mutation | c.2006N>T | p.Ala669Val | p.A669V | Q03519 | protein_coding | deleterious(0.03) | benign(0.174) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
TAP2 | SNV | Missense_Mutation | novel | c.1053N>C | p.Glu351Asp | p.E351D | Q03519 | protein_coding | deleterious(0) | possibly_damaging(0.677) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
TAP2 | SNV | Missense_Mutation | rs376467259 | c.1028N>A | p.Arg343His | p.R343H | Q03519 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAP2 | SNV | Missense_Mutation | c.977N>T | p.Ala326Val | p.A326V | Q03519 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |